Huahai Pharmaceutical: Subsidiary HB0025 Injection Initiates Phase III Clinical Trial for Endometrial Cancer

Hua Hai Pharmaceutical Co., Ltd. announced that its subsidiary, Shanghai Hua’otai Biopharmaceutical Co., Ltd., has, following meeting communications with the National Medical Products Administration’s Center for Drug Evaluation before the completion of the Phase II clinical trial / the initiation of the Phase III clinical trial for HB0025 combined chemotherapy in first-line treatment of advanced / recurrent endometrial cancer, officially launched the Phase III clinical trial of HB0025 injection for endometrial cancer. HB0025 is an innovative anti–PD-L1/VEGF bispecific fusion protein independently developed by Hua’otai. It simultaneously targets the tumor immune escape pathway PD-L1 and the tumor angiogenesis pathway VEGF. The design of this drug achieves high-affinity binding to two targets, coordinating and regulating the tumor immune microenvironment and angiogenesis, and has a dual anti-tumor mechanism of “immune enhancement + anti-angiogenesis.”